ABSTRACT
INTRODUCTION: Current research shows no increased risk of thromboembolic events with mild COVID-19 but does not account for comorbidities. The aim of this study was to examine the incidence of thromboembolic events, including pulmonary embolism, cerebral infarction, and deep vein thrombosis, in nonhospitalized patients diagnosed with COVID-19 while accounting for comorbidities such as diabetes, asthma, COPD and cancer. METHODS: We completed a large retrospective observational analysis of adult patients within a large urban health system. RESULTS: Using a logit framework (with and without propensity score weighting), there was no increased risk of thromboembolic events among patients positive for SARS-CoV-2 who did not require hospitalization for COVID-19. CONCLUSION: This data suggest prophylactic anticoagulation is likely not warranted in the outpatient setting.